Webinar, Wednesday, August 23, 2017; 7 p.m. - 8 p.m. Eastern

Join us for a free webinar in the comfort of your own home hosted by Dr. Dinesh Khanna from the University of Michigan on Managing GI Involvement. There is no sign-up necessary. Join the meeting here just prior to the start time.

15th International Workshop on Scleroderma Research

The abstracts from the 15th International Workshop on Scleroderma Research are published free in the Journal of Scleroderma and Related Disease.

Based on current legislative priorities in Washington, DC and the realities of introducing a bill into Congress in the near future, Capitol Hill Day 2017 (originally scheduled for October 25) has been rescheduled for Spring 2018.

Advocacy work to advance our cause will continue this fall and winter through grassroots efforts in congressional districts, advocacy alerts and training opportunities for current and new scleroderma advocates. There was an outstanding workshop at the recent patient education conference focused specifically on how to utilize one’s story as a powerfully effective tool to share with legislators in hopes that the elected official will co-sponsor a bill. That process is even more effective when there is a bill before Congress to co-sponsor! Training opportunities will be announced in future e-newsletters, and the date for Capitol Hill Day 2018 will be announced as soon as it is confirmed.

Read more

Discovery Documentary: First in Human

First in Human is a three-part documentary capturing the real-life experiences of doctors, researchers, staff, patients and their caregivers, at the NIH Clinical Center.* The documentary airs on three sequential Thursday evenings on August 10, 17, and 24, at 9:00 p.m. ET/PT on Discovery.

Read more

Holistic Approach Helps Patients Engage in Care

Article from the Pulmonary Hypertension Association about patient engagement in their own care, by Phyllis Hanlon, Contributing Writer.

Read more

Corbus Pharmaceuticals issued a press release with an update on trials for Anabasum, their synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrosis. Update includes Data from Phase 2 open-label extension study of anabasum for the treatment of systemic sclerosis expected in Q4 2017. And, Phase 3 study of anabasum for the treatment of system sclerosis expected to commence in Q4 2017.

Read more